|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Adam S. Grossman||Co-Founder, Pres, CEO & Director||824,76k||N/D||1977|
|Dr. Jerrold B. Grossman Ph.D., D.P.S.||Co-Founder & Vice Chairman||65,92k||N/D||1948|
|Mr. Brian Lenz CPA, CPA||Exec. VP & CFO||627,86k||N/D||1972|
|Dr. James Mond||Exec. VP, Chief Scientific Officer & Chief Medical Officer||733,22k||N/D||1946|
|Ms. Kaitlin Kestenberg||VP of Compliance, Project Management & Clinical Operations||N/D||N/D||N/D|
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
L'ISS Governance QualityScore di ADMA Biologics, Inc. al 3 dicembre 2019 è 10. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 8; diritti degli azionisti: 9; retribuzione: 10.